Compumedics Limited · ASX:CMP
Compumedics — Investor Presentation (October 2018)
22 slides from Compumedics's investor presentation, October 2018
Slide 1: Corporate presentation
Corporate presentation September 2016 David Burton – Chairman, CEO dburton@compumedics.com.au David Lawson – Director, CFO dlawson@compumedics.com.au Sleep Diagnostics & Treatment - Neuro Diagnostics - Brain Research - Ultrasonic Blood Flow Monitoring1
Slide 2: Who is Compumedics?
Who is Compumedics? A leading global, innovative developer and manufacturer of medical devices for: Monitoring Ultrasonic monitoring neurological disorders Diagnosing Highly sophisticated of blood flow through including long-term sleep disorders brain research the brain (Transcranial epilepsy monito
Slide 3: FY2018 – Performance Review
FY2018 – Performance Review ▪ FY17 Revenue (reported) $37.0m, EBITDA (reported) $4.2m, NPAT (reported) $2.8m FY18 FY17 Variance Comment Sales growth across key international markets for Revenue - reported $37.0m $34.4m 8% the core business, including China, Europe, DWL and US. Partial booking of fir
Slide 4: FY2018 – Performance Review
FY2018 – Performance Review ▪ Core: US business grows 8%, albeit at slower rates than expected. Europe and DWL also grow in FY18, compared to FY17 ▪ Core: Asia business and China in particular strong with 28% lift in sales over pcp. ▪ Core: Profitability grows as a result of the overall growth in sa
Slide 5: Sales Bridge Chart – FY17 versus FY18
Sales Bridge Chart – FY17 versus FY18 40 35 30 25 20 15 10 5 0 Sales FY17 USA Aust Asia Europe Sales FY18 Fall Rise 5
Slide 6: EBITDA movement – FY17 versus FY18
EBITDA movement – FY17 versus FY18 6 5 4 3 2 1 0 EBITDA FY17 Sales Margin Expenses Other FX EBITDA FY18 Revenues Fall Rise 6
Slide 7: Revenue Composition at $37.0m
Revenue Composition at $37.0m 30 June 2018 By geographic region By product/market Tech. Supply Service, Europe, 21% Brain Items, 9% 9% USA, Blood 32% Flow, 17% Sleep, 33% Asia, Brain Res, Aust, 18% 33% 14% Neuro, 14% Software upgrades 5 to 10% of system sales Compumedics sells directly to end-user c
Slide 8: Growth Platform – Core and Step-Out
Growth Platform – Core and Step-Out Sales – schematic only FY18F FY19F FY20F FY21F FY22F Core - Base Core - Sleep/Neuro (Mid Market) Neuro - MEG Sleep - eHealth (Nexus360 & Somfit) • Step-out - NEURO – BRAIN IMAGING – Installation at Barrow Neurological Institute in Phoenix, AZ, USA is continuing an
Slide 9: Core Business – Premium Focus
Core Business – Premium Focus Neuro Neuro Sleep Brain Blood Diagnostics – Diagnostics - Diagnostics Flow Diagnostics Clinic Research Global market – 250m 1,300m 20m 15m USD pa Compumedics market share 6% <1% 30% 35% (approximate) Aust – 1 Aust – 1 Aust – 1 Aust – 1 Compumedics USA – 2 USA – 3 USA –
Slide 10: Core Business – Growing revenues and profits
Core Business – Growing revenues and profits 40,000 6,000 35,000 5,000 30,000 4,000 25,000 3,000 20,000 2,000 15,000 1,000 10,000 - 5,000 -1,000 - -2,000 2012 2013 2014 2015 2016 2017 2018 Revenues EBITDA 1.2000 AUD/USD exchange rate 1.0324 1.0271 1.0000 0.9188 0.8386 0.7426 0.7424 0.7751 0.8000 0.6
Slide 11: Core Business – Net Cash Position maintained
Core Business – Net Cash Position maintained $m FY12 FY13 FY14 FY15 FY16 FY17 FY18 Cash 1.1 1.3 1.1 2.2 3.1 4.1 3.9 Trade receivables 8.7 8.1 8.6 9.8 11.9 13.1 18.3 Inventories 5.3 5.5 6.1 5.7 6.5 7.4 7.6 Prod. dev’t 4.0 3.5 2.9 2.7 2.4 2.4 4.0 Tax asset 0.0 0.0 0.0 0.0 0.5 0.8 0.1 PP&E 0.8 0.7 0.7
Slide 12: Core Business – Adding Mid-Tier Range
Core Business – Adding Mid-Tier Range Average Product Used for Bought by selling price Sleep and neurology, high end and Hospitals, doctors USD11,500 to Grael family price sensitive models and service providers USD17,500 Hospitals, doctors Somte PSG Sleep USD10,000 and service providers Hospitals, d
Slide 13: Next Generation Growth – Core and Step-out
Next Generation Growth – Core and Step-out Neuro Sleep Neuro Brain Blood Diagnostics – Diagnostics Diagnostics - Imaging Flow Diagnostics Clinic Cloud based sleep Leverage existing Long term epilepsy diagnostic platforms Leverage CURRY TCD technology and Next generation market penetration for both p
Slide 14: Core Business - Growth Drivers
Core Business - Growth Drivers Compumedics/NeuroScan LTEM innovative brain analysis software and high performance amplifiers are unrivalled world class technology. With the release of new innovative electrode array designs, a larger growth is anticipated in direct sales, with a resulting increase in
Slide 15: USA – CMP is number 3 Supplier
USA – CMP is number 3 Supplier USA Clinical Sales Force Expansion - Indicative More sales representatives = more revenue for both sleep and neurology Past USD3.0m FY2018 to now USD4.0m FY2019 USD7.0m FY2020 USD11.0m 15
Slide 16: China - We are the number 1 Premier Supplier
China - We are the number 1 Premier Supplier Compumedics Clients in China Sleep Neuroscience Neuroscan 28 2 Xin Jiang 5 Helongjiang Inner Mongolia 2 Jilin Beijing 88 2 Liaoning Ningxia 23 Qinhuangdao China Sales (invoiced) – USD’s QingHai 3 HeBei 10 3 Tianjin Dalian 2 3 16 12 7.6 Gansu 14 HeNan Shan
Slide 17: Step out - Brain Imaging: 1st sale secured
Step out 1 - Brain Imaging: 1st sale secured Opportunity Market & Competition Plan Outcome CMP’s CURRY brain analysis The MEG market is currently H1 FY19 – complete CMP plans to sell software is already the gold estimated at about 20 systems a first installation at US and install 1 MEG standard for
Slide 18: Step out - eHealth – Cloud Sleep Diagnostics
Step out 2 - eHealth – Cloud Sleep Diagnostics Nexus 360 Operational systems have been Compumedics are now Key partners (professional developed for the cloud based approaching being pursued cloud sleep capture, transfer a select group of continue to diagnostics) sold and translation of medical grade
Slide 19: Directors & Executive Team Key Management
Directors & Executive Team Key Management David Burton, Ph.D. Executive Chairman, CEO Founder, Tenure 31yrs Alan Anderson Ph.D. Mr Tucson Dunn Mr. David Lawson Non Executive Director Non Executive Director Chief Financial Officer CMP Tenure : 18 yrs CMP Tenure 6 months & Company Secretary CMP Tenure
Slide 20: Investor Summary
Investor Summary Core business profitable with on-going growth opportunities in key global markets International sales force Compumedics remains expansion, neurology and sleep committed to continuing to market opportunity and earnings deliver superior returns to improvement initiatives to shareholde
Slide 21: Disclaimer
Disclaimer This presentation has been prepared by Compumedics Ltd (CMP). While the information in this presentation has been prepared in good faith and with reasonable care, no representation or warranty, express or implied, is made as to the accuracy, adequacy or reliability of any statement, estim
Slide 22: compumedics.com.au
compumedics.com.au22